New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new data across its dermatologic portfolio of gene expression profile (GEP) tests at the 2023 Fall Clinical Dermatology Conference (FC23), taking place Oct. 19-22, 2023, in Las Vegas.

“The breadth of data we are sharing at Fall Clinical reinforces our commitment to improving the care of patients with skin cancers and inflammatory skin conditions through innovative tests that can guide more informed disease management decisions,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.

Details regarding Castle’s posters at FC23 are included below. Posters will be available for viewing for the duration of the conference.

• Using 31-gene expression profile testing to help guide adjuvant therapy and sentinel lymph node biopsy discussions with patients: A case series
  Lead Author: Peter Prieto, M.D., MPH, University of Rochester Medical Center

• Association of a 40-gene expression profile with risk of metastatic disease progression of cutaneous squamous cell carcinoma (cSCC) and benefit of adjuvant radiation therapy (ART)
  Lead Author: Sarah Arron, M.D., Ph.D., Peninsula Dermatology

• Incorporating the 40-gene expression profile (40-GEP) test within each clinicopathologic staging system improves metastatic risk-stratification in patients diagnosed with cutaneous squamous cell carcinoma (cSCC) and one or more high risk factors
  Lead Author: Ashley Wysong, M.D., M.S., University of Nebraska Medical Center

• Use of the 40-gene expression profile (40-GEP) test in Medicare-eligible patients diagnosed with cutaneous squamous cell carcinoma (cSCC) to guide adjuvant radiation therapy (ART) decisions leads to a significant reduction in healthcare costs
  Lead Authors: Anesh Prasai, Ph.D., Castle Biosciences, and Matthew S. Goldberg, M.D., Castle Biosciences and Icahn School of Medicine at Mount Sinai

• Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi-center performance cohort of cutaneous melanocytic neoplasms
  Lead Author: Matthew S. Goldberg, M.D., Castle Biosciences and Icahn School of Medicine at Mount Sinai

• Gene expression differences identified in skin samples of early-stage mycosis fungoides, atopic dermatitis, and psoriasis
  Lead Author: Aaron S. Farberg, M.D., Baylor Scott & White Health System and Bare Dermatology
  Specific details regarding this poster will be shared following the FC23 conference.

About DecisionDx-Melanoma